IPO - Marex Group plc

Form Type: 424B4

Filing Date: 2025-04-17

Corporate Action: Ipo

Type: New

Accession Number: 000119312525083415

Filing Summary: Marex Group plc registered a total of 10,283,802 ordinary shares for sale by selling shareholders, with no proceeds going to the company itself. The ordinary shares typically have a nominal value of $0.001551 each and are listed on the Nasdaq Global Select Market under the symbol 'MRX'. The anticipated price to the public is $35.50 per share, with a last reported price of $38.11 noted on April 16, 2025. This offering involves underwriting by several financial institutions, and includes an over-allotment option for an additional 1,542,570 shares. The document indicates that there are inherent risks involved in investing in these shares. The underwriters are expected to deliver the shares on April 17, 2025, marking an important date for the public offering of Marex Group's shares, indicating the company's strategy to enter capital markets more significantly following multiple acquisitions in the prior years.

Form Type: F-1MEF

Filing Date: 2025-04-16

Corporate Action: Ipo

Type: New

Accession Number: 000119312525083102

Filing Summary: On April 16, 2025, Marex Group plc filed a registration statement with the U.S. Securities and Exchange Commission, designated as Form F-1MEF, for a public offering of ordinary shares. This filing serves to register an additional 2,051,372 shares, including an option for underwriters to purchase 267,570 shares. The registration statement references an earlier filed Form F-1 (File No. 333-286522) that was initially filed on April 14, 2025 and declared effective on the same day. The shares are to be offered at a nominal value of $0.001551 per share, representing up to 20% of the maximum aggregate offering price detailed in the related filing. Marex Group plc’s principal executive offices are located in London, United Kingdom, with a designated agent for service based in New York, USA. The SEC registration indicates that the offering is anticipated to commence as soon as the registration statement becomes effective.

Form Type: CORRESP

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000119312525080216

Filing Summary: Marex Group plc requests the acceleration of the effective date for its Registration Statement on Form F-1 (File No. 333-286522) as per Rule 461 of Regulation C under the Securities Act of 1933. The company asks for the Registration Statement to become effective at 4:00 p.m. Eastern Time on April 16, 2025, or as soon as practicable afterwards. The request also includes a direction to confirm this event orally with their counsel at Latham & Watkins LLP. The correspondence is signed by Ian Lowitt, the Chief Executive Officer of Marex Group plc, and copies are sent to various individuals from the company and legal representatives.

Form Type: CORRESP

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000119312525080221

Filing Summary: On April 14, 2025, Marex Group plc filed a correspondence letter with the SEC regarding their Registration Statement on Form F-1 for an initial public offering (IPO). The letter informs that the underwriters have distributed approximately 1,500 copies of the Preliminary Prospectus dated the same day to underwriters, dealers, and other institutions. The representatives of the underwriters have assured compliance with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, and they request the acceleration of the Registration Statement's effectiveness to 4:00 p.m., Eastern Time, on April 16, 2025. The correspondence is signed by representatives from Goldman Sachs & Co. LLC, Barclays Capital Inc., and Jefferies LLC, affirming their roles in the underwriting syndicate for the offering.

Form Type: F-1

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000119312525080157

Filing Summary: Marex Group plc filed a registration statement on Form F-1 with the SEC on April 14, 2025, to register 8,500,000 ordinary shares with a nominal value of $0.001551 for sale by selling shareholders. The shares are listed on Nasdaq under the symbol 'MRX'. The filing indicates that Marex will not be selling any shares and will not receive any proceeds from this offering. The ordinary shares offering will commence as soon as practicable after the effective date of this registration statement. The last reported price for the shares as of April 11, 2025, was $37.42. The document provides details about the offerings, including risks, financial data, and other corporate disclosures necessary for potential investors, highlighting the company's status as a foreign private issuer under SEC rules, which allows for reduced disclosure requirements. The document discusses past acquisitions and company structure but does not categorize any individual acquisitions as significant according to SEC regulations. This F-1 filing serves as a preliminary prospectus subject to completion and further regulatory approvals.

Form Type: DRS

Filing Date: 2025-04-08

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003362

Filing Summary: Marex Group plc filed a draft registration statement on Form F-1 for an initial public offering (IPO) of its ordinary shares. The registration statement is confidential and has not been publicly filed with the SEC, indicating it is in the preliminary stages. The selling shareholders are offering shares that have a nominal value of $0.001551 per ordinary share, with Marex not selling any of its shares or receiving proceeds from this offering. The ordinary shares are listed under the symbol 'MRX' on the Nasdaq Global Select Market. Significant risks, financials, and other relevant details are outlined for prospective investors, with the expectation of shares being sold once the registration statement becomes effective. The document also notes that Marex has undertaken several acquisitions, starting from 2022 up to 2025, which contributed to its current market posture and financial state. A reverse stock split occurred prior to the IPO, affecting share listings and financial representations.